Nextrast Inc

New Dark Borosilicate Contrast Agent Shows Promise for Enhanced CT Imaging of Bowel Pathologies

- A pilot study of 32 patients found that a new dark borosilicate oral contrast agent improved CT imaging visualization of bowel structures compared to conventional water- and iodine-based agents. - Radiologists identified clinically relevant findings in seven patients using the new agent that were missed with standard contrast agents, including small bowel tumors and inflammatory conditions. - The FDA-cleared agent specifically enhances image clarity in the stomach and proximal small bowel, areas where traditional CT contrast performs poorly. - Researchers suggest the new agent may enable earlier detection of cancers and inflammatory bowel disease, though larger trials are needed to validate these findings.